<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499119</url>
  </required_header>
  <id_info>
    <org_study_id>20160172</org_study_id>
    <nct_id>NCT03499119</nct_id>
  </id_info>
  <brief_title>AMG 334 20160172 Pediatric Migraine PK Study.</brief_title>
  <official_title>A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AMG 334 20160172 Pediatric Migraine PK Study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Randomized, Multiple-dose Study to Evaluate Safety, Tolerability, and
      Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 18, 2018</start_date>
  <completion_date type="Anticipated">March 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum PK parameter of AMG 334 time to maximum observed concentration [Cmax]</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter of AMG 334 time to maximum concentration [tmax]</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter of AMG 334 area under the concentration time cure from 0 to 28 days [AUC 0-28days]</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter of AMG 334 area under concentration time curve [AUC]</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PK parameter of AMG 334 time to trough concentration [Ctrough]</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and morphology of P, QRS and T waves in 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard Hematology Lab Assessments</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard Chemistry</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Including liver function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard sensory assessment of body and peripheral and central nervous systems</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard motor assessment of body peripheral and central nervous systems</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with a body weight at Day 1 of less than weight threshold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with a body weight at Day 1 of weight threshold or more.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 334 Dose 1</intervention_name>
    <description>Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
Subjects weighting weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 334 Dose 2</intervention_name>
    <description>Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 334 Dose 3</intervention_name>
    <description>Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's legally acceptable representative has provided informed consent and the
             subject has provided written assent based on local regulations and/or guidelines prior
             to any study-specific activities/procedures being initiated.

          -  Male and female children and adolescents ≥ 6 and &lt;18 years of age upon entry into
             screening

          -  Diagnosis of migraines, with or without aura, according to the International
             Classification of Headache Disorders (ICHD 3rd Edition, 2013) for at least 12 months
             prior to the study screening

          -  Frequency of migraine of ≥ 4 migraine days per month in each of the 3 months prior to
             the study screening period

        Exclusion Criteria:

          -  Currently receiving treatment in another investigational device or drug study -History
             of migraine with brainstem aura or hemiplegic migraine headache

          -  Medical history or other condition that compromises the ability of the subject or
             legally acceptable representative to give appropriate informed consent and/or assent

          -  Malignancy except non-melanoma skin cancers or cervical cancer in situ within the last
             5 years.

          -  Presence of any clinical condition that in opinion of the investigator might increased
             the risk of subjects participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

